The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
Identifieur interne : 000A20 ( Main/Exploration ); précédent : 000A19; suivant : 000A21The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
Auteurs : W. Hugenholtz-Wamsteker [Pays-Bas] ; C. Robbeson [Pays-Bas] ; J. Nijs [Pays-Bas] ; W. Hoelen [Pays-Bas] ; M. Meeus [Pays-Bas]Source :
- European journal of cancer care [ 1365-2354 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- usage thérapeutique : Antinéoplasiques, Taxoïdes.
- épidémiologie : Complications postopératoires, Lymphoedème, Oedème.
- Facteurs de risque, Femelle, Humains, Mastectomie, Traitement médicamenteux adjuvant, Tumeurs du sein.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Taxoids.
- epidemiology : Edema, Lymphedema, Postoperative Complications.
- therapy : Breast Neoplasms.
- Chemotherapy, Adjuvant, Female, Humans, Mastectomy, Risk Factors.
Abstract
Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel-treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.
DOI: 10.1111/ecc.12261
PubMed: 25348689
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001235
- to stream PubMed, to step Curation: 001235
- to stream PubMed, to step Checkpoint: 001235
- to stream Ncbi, to step Merge: 006C57
- to stream Ncbi, to step Curation: 006C57
- to stream Ncbi, to step Checkpoint: 006C57
- to stream Main, to step Merge: 000A21
- to stream Main, to step Curation: 000A20
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.</title><author><name sortKey="Hugenholtz Wamsteker, W" sort="Hugenholtz Wamsteker, W" uniqKey="Hugenholtz Wamsteker W" first="W" last="Hugenholtz-Wamsteker">W. Hugenholtz-Wamsteker</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Robbeson, C" sort="Robbeson, C" uniqKey="Robbeson C" first="C" last="Robbeson">C. Robbeson</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Nijs, J" sort="Nijs, J" uniqKey="Nijs J" first="J" last="Nijs">J. Nijs</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Hoelen, W" sort="Hoelen, W" uniqKey="Hoelen W" first="W" last="Hoelen">W. Hoelen</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Meeus, M" sort="Meeus, M" uniqKey="Meeus M" first="M" last="Meeus">M. Meeus</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:25348689</idno><idno type="pmid">25348689</idno><idno type="doi">10.1111/ecc.12261</idno><idno type="wicri:Area/PubMed/Corpus">001235</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001235</idno><idno type="wicri:Area/PubMed/Curation">001235</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001235</idno><idno type="wicri:Area/PubMed/Checkpoint">001235</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001235</idno><idno type="wicri:Area/Ncbi/Merge">006C57</idno><idno type="wicri:Area/Ncbi/Curation">006C57</idno><idno type="wicri:Area/Ncbi/Checkpoint">006C57</idno><idno type="wicri:Area/Main/Merge">000A21</idno><idno type="wicri:Area/Main/Curation">000A20</idno><idno type="wicri:Area/Main/Exploration">000A20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.</title><author><name sortKey="Hugenholtz Wamsteker, W" sort="Hugenholtz Wamsteker, W" uniqKey="Hugenholtz Wamsteker W" first="W" last="Hugenholtz-Wamsteker">W. Hugenholtz-Wamsteker</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Robbeson, C" sort="Robbeson, C" uniqKey="Robbeson C" first="C" last="Robbeson">C. Robbeson</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Nijs, J" sort="Nijs, J" uniqKey="Nijs J" first="J" last="Nijs">J. Nijs</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Hoelen, W" sort="Hoelen, W" uniqKey="Hoelen W" first="W" last="Hoelen">W. Hoelen</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author><author><name sortKey="Meeus, M" sort="Meeus, M" uniqKey="Meeus M" first="M" last="Meeus">M. Meeus</name><affiliation wicri:level="1"><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden</wicri:regionArea><wicri:noRegion>Hierden</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of cancer care</title><idno type="eISSN">1365-2354</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Breast Neoplasms (therapy)</term><term>Chemotherapy, Adjuvant</term><term>Edema (epidemiology)</term><term>Female</term><term>Humans</term><term>Lymphedema (epidemiology)</term><term>Mastectomy</term><term>Postoperative Complications (epidemiology)</term><term>Risk Factors</term><term>Taxoids (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Complications postopératoires (épidémiologie)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lymphoedème (épidémiologie)</term><term>Mastectomie</term><term>Oedème (épidémiologie)</term><term>Taxoïdes (usage thérapeutique)</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs du sein ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Edema</term><term>Lymphedema</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Taxoïdes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Complications postopératoires</term><term>Lymphoedème</term><term>Oedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Humans</term><term>Mastectomy</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Mastectomie</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs du sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel-treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Hugenholtz Wamsteker, W" sort="Hugenholtz Wamsteker, W" uniqKey="Hugenholtz Wamsteker W" first="W" last="Hugenholtz-Wamsteker">W. Hugenholtz-Wamsteker</name></noRegion><name sortKey="Hoelen, W" sort="Hoelen, W" uniqKey="Hoelen W" first="W" last="Hoelen">W. Hoelen</name><name sortKey="Meeus, M" sort="Meeus, M" uniqKey="Meeus M" first="M" last="Meeus">M. Meeus</name><name sortKey="Nijs, J" sort="Nijs, J" uniqKey="Nijs J" first="J" last="Nijs">J. Nijs</name><name sortKey="Robbeson, C" sort="Robbeson, C" uniqKey="Robbeson C" first="C" last="Robbeson">C. Robbeson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25348689
|texte= The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25348689" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |